1
WGU D116 Advanced Pharmacology Final Exam
Actual Exam 2026/2027 – Complete Exam-Style
Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
[SECTION 1: Pharmacokinetics & Pharmacodynamics — Questions 1-18]
Q1: A nurse practitioner is prescribing a drug that undergoes extensive "first-pass metabolism."
What is the clinical implication of this property?
A. A significant portion of the drug is metabolized by the liver before reaching systemic
circulation, often requiring a higher oral dose.
B. The drug must be administered parenterally to avoid renal failure.
C. The drug has a very high bioavailability when taken orally.
D. The drug is excreted unchanged by the kidneys.
Correct Answer: A
Rationale: First-pass metabolism refers to the metabolism of a drug by the liver after absorption
from the GI tract but before it enters the systemic circulation. Drugs with high first-pass
extraction (e.g., propranolol, lidocaine, nitroglycerin) have significantly reduced oral
bioavailability and often require alternative routes (sublingual, IV) or higher doses. Options C
and D are incorrect because first-pass metabolism lowers bioavailability and involves hepatic
metabolism, not renal excretion.
Q2: A patient with a history of liver failure requires a medication that is extensively metabolized
by the Cytochrome P450 system. Which pharmacokinetic change is expected?
A. Increased absorption
C. Decreased metabolism leading to potential drug accumulation and toxicity.
D. Increased renal excretion
E. Increased protein binding
,2
Correct Answer: C
Rationale: The liver is the primary site of drug metabolism, particularly via the Cytochrome
P450 enzyme system. In liver failure, metabolic capacity is reduced, leading to decreased
clearance of hepatically cleared drugs. This can cause significant accumulation of the drug and
potential toxicity, necessitating lower dosages. Absorption and renal excretion are not directly
impacted in the same way.
Q3: Which Cytochrome P450 enzyme is responsible for the metabolism of the largest number of
drugs and is a major site of drug-drug interactions?
A. CYP2D6
B. CYP2C9
C. CYP3A4
D. CYP1A2
Correct Answer: C
Rationale: CYP3A4 is the most abundant Cytochrome P450 enzyme in the liver and intestines
and metabolizes approximately 50% of all drugs. Because of its abundance, it is the most
common site of drug-drug interactions (e.g., inhibitors like grapefruit juice or inducers like
rifampin). CYP2D6, 2C9, and 1A2 metabolize fewer drugs.
Q4: A patient taking Carbamazepine (an enzyme inducer) starts taking an oral contraceptive.
What is the likely outcome?
A. Increased risk of thromboembolism.
B. Increased effectiveness of the antidepressant.
C. Decreased effectiveness of the oral contraceptive leading to potential breakthrough bleeding
and unplanned pregnancy.
D. Increased risk of Carbamazepine toxicity.
Correct Answer: C
Rationale: Carbamazepine is a potent inducer of CYP3A4, which increases the metabolism of
estrogen and progestins in oral contraceptives. This leads to decreased hormone levels and
,3
reduced effectiveness, often resulting in breakthrough bleeding and unintended pregnancy. The
patient should be counseled to use a non-hormonal backup method.
Q5: A drug is described as having a "narrow therapeutic index." What does this mean for
prescribing?
A. The drug is very safe and can be dosed liberally.
C. The difference between the therapeutic dose and the toxic dose is small, requiring careful
monitoring.
D. The drug has a long half-life.
E. The drug is effective only at high doses.
Correct Answer: C
Rationale: A narrow therapeutic index (TI) means there is a small margin between the minimum
effective concentration and the toxic concentration. Drugs like Warfarin, Lithium, Digoxin, and
Phenytoin require strict monitoring (blood levels) and precise dosaging adjustments to avoid
toxicity. Safe drugs with wide TIs (e.g., penicillins) have a large margin of safety.
Q6: What is the mechanism of action of a "competitive antagonist"?
A. Binds to the same receptor site as the agonist, preventing the agonist from binding.
B. Binds to a different site on the receptor, changing its shape.
C. Activates the receptor to a sub-maximal degree.
D. Permanently disables the receptor.
Correct Answer: A
Rationale: A competitive antagonist competes directly with the agonist for the binding site on the
receptor. Its effects can be overcome by increasing the concentration of the agonist. A non-
competitive antagonist binds to an allosteric site (different site) and cannot be overcome by more
agonist.
, 4
Q7: A patient is taking a drug that is highly protein bound (98%). What happens if another drug
with high protein affinity is administered?
A. No effect, because proteins regenerate quickly.
B. Free drug decreases.
C. Displacement of the first drug, potentially increasing its free (active) concentration and effect.
D. Metabolism increases immediately.
Correct Answer: C
Rationale: Drugs bind to plasma proteins (albumin, alpha-1 acid glycoprotein) to varying
degrees. If two drugs compete for the same binding site, the drug with higher affinity can
displace the first, increasing the free (pharmacologically active) concentration of the displaced
drug. This can lead to transient toxicity or increased effect.
Q8: A drug has a "Volume of Distribution" (Vd) that is very high (e.g., >100 L). What does this
indicate?
A. The drug is extensively distributed into tissues (e.g., adipose tissue, organs) rather than
staying in the blood.
B. The drug is mostly confined to the plasma.
C. The drug is rapidly excreted by the kidneys.
D. The drug has low lipid solubility.
Correct Answer: A
Rationale: A high Vd indicates that the drug is extensively distributed from the plasma into the
tissues (e.g., lipophilic drugs stored in fat). A low Vd (e.g., 3-5 L) indicates the drug remains
largely in the plasma compartment.
Q9: Which Phase II metabolic reaction involves the addition of a glucuronic acid moiety to a
drug, making it more water-soluble for excretion?
A. Oxidation
B. Hydrolysis
WGU D116 Advanced Pharmacology Final Exam
Actual Exam 2026/2027 – Complete Exam-Style
Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
[SECTION 1: Pharmacokinetics & Pharmacodynamics — Questions 1-18]
Q1: A nurse practitioner is prescribing a drug that undergoes extensive "first-pass metabolism."
What is the clinical implication of this property?
A. A significant portion of the drug is metabolized by the liver before reaching systemic
circulation, often requiring a higher oral dose.
B. The drug must be administered parenterally to avoid renal failure.
C. The drug has a very high bioavailability when taken orally.
D. The drug is excreted unchanged by the kidneys.
Correct Answer: A
Rationale: First-pass metabolism refers to the metabolism of a drug by the liver after absorption
from the GI tract but before it enters the systemic circulation. Drugs with high first-pass
extraction (e.g., propranolol, lidocaine, nitroglycerin) have significantly reduced oral
bioavailability and often require alternative routes (sublingual, IV) or higher doses. Options C
and D are incorrect because first-pass metabolism lowers bioavailability and involves hepatic
metabolism, not renal excretion.
Q2: A patient with a history of liver failure requires a medication that is extensively metabolized
by the Cytochrome P450 system. Which pharmacokinetic change is expected?
A. Increased absorption
C. Decreased metabolism leading to potential drug accumulation and toxicity.
D. Increased renal excretion
E. Increased protein binding
,2
Correct Answer: C
Rationale: The liver is the primary site of drug metabolism, particularly via the Cytochrome
P450 enzyme system. In liver failure, metabolic capacity is reduced, leading to decreased
clearance of hepatically cleared drugs. This can cause significant accumulation of the drug and
potential toxicity, necessitating lower dosages. Absorption and renal excretion are not directly
impacted in the same way.
Q3: Which Cytochrome P450 enzyme is responsible for the metabolism of the largest number of
drugs and is a major site of drug-drug interactions?
A. CYP2D6
B. CYP2C9
C. CYP3A4
D. CYP1A2
Correct Answer: C
Rationale: CYP3A4 is the most abundant Cytochrome P450 enzyme in the liver and intestines
and metabolizes approximately 50% of all drugs. Because of its abundance, it is the most
common site of drug-drug interactions (e.g., inhibitors like grapefruit juice or inducers like
rifampin). CYP2D6, 2C9, and 1A2 metabolize fewer drugs.
Q4: A patient taking Carbamazepine (an enzyme inducer) starts taking an oral contraceptive.
What is the likely outcome?
A. Increased risk of thromboembolism.
B. Increased effectiveness of the antidepressant.
C. Decreased effectiveness of the oral contraceptive leading to potential breakthrough bleeding
and unplanned pregnancy.
D. Increased risk of Carbamazepine toxicity.
Correct Answer: C
Rationale: Carbamazepine is a potent inducer of CYP3A4, which increases the metabolism of
estrogen and progestins in oral contraceptives. This leads to decreased hormone levels and
,3
reduced effectiveness, often resulting in breakthrough bleeding and unintended pregnancy. The
patient should be counseled to use a non-hormonal backup method.
Q5: A drug is described as having a "narrow therapeutic index." What does this mean for
prescribing?
A. The drug is very safe and can be dosed liberally.
C. The difference between the therapeutic dose and the toxic dose is small, requiring careful
monitoring.
D. The drug has a long half-life.
E. The drug is effective only at high doses.
Correct Answer: C
Rationale: A narrow therapeutic index (TI) means there is a small margin between the minimum
effective concentration and the toxic concentration. Drugs like Warfarin, Lithium, Digoxin, and
Phenytoin require strict monitoring (blood levels) and precise dosaging adjustments to avoid
toxicity. Safe drugs with wide TIs (e.g., penicillins) have a large margin of safety.
Q6: What is the mechanism of action of a "competitive antagonist"?
A. Binds to the same receptor site as the agonist, preventing the agonist from binding.
B. Binds to a different site on the receptor, changing its shape.
C. Activates the receptor to a sub-maximal degree.
D. Permanently disables the receptor.
Correct Answer: A
Rationale: A competitive antagonist competes directly with the agonist for the binding site on the
receptor. Its effects can be overcome by increasing the concentration of the agonist. A non-
competitive antagonist binds to an allosteric site (different site) and cannot be overcome by more
agonist.
, 4
Q7: A patient is taking a drug that is highly protein bound (98%). What happens if another drug
with high protein affinity is administered?
A. No effect, because proteins regenerate quickly.
B. Free drug decreases.
C. Displacement of the first drug, potentially increasing its free (active) concentration and effect.
D. Metabolism increases immediately.
Correct Answer: C
Rationale: Drugs bind to plasma proteins (albumin, alpha-1 acid glycoprotein) to varying
degrees. If two drugs compete for the same binding site, the drug with higher affinity can
displace the first, increasing the free (pharmacologically active) concentration of the displaced
drug. This can lead to transient toxicity or increased effect.
Q8: A drug has a "Volume of Distribution" (Vd) that is very high (e.g., >100 L). What does this
indicate?
A. The drug is extensively distributed into tissues (e.g., adipose tissue, organs) rather than
staying in the blood.
B. The drug is mostly confined to the plasma.
C. The drug is rapidly excreted by the kidneys.
D. The drug has low lipid solubility.
Correct Answer: A
Rationale: A high Vd indicates that the drug is extensively distributed from the plasma into the
tissues (e.g., lipophilic drugs stored in fat). A low Vd (e.g., 3-5 L) indicates the drug remains
largely in the plasma compartment.
Q9: Which Phase II metabolic reaction involves the addition of a glucuronic acid moiety to a
drug, making it more water-soluble for excretion?
A. Oxidation
B. Hydrolysis
